載入...
Optimizing Treatment Outcomes With Regorafenib: Personalized Dosing and Other Strategies to Support Patient Care
Regorafenib is an oral multikinase inhibitor that inhibits several kinases relevant to tumor biology in several cancers, including colorectal carcinoma (CRC) and gastrointestinal stromal tumor (GIST). In phase III trials, regorafenib significantly improved overall survival versus placebo in patients...
Na minha lista:
| Main Authors: | , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
AlphaMed Press
2014
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4041675/ https://ncbi.nlm.nih.gov/pubmed/24821824 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2013-0059 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|